In patients with type 1 diabetes treated with multiple daily insulin injections or continuous subcutaneous insulin infusion, there is convincing evidence that the use of real‐time CGM can significantly reduce HbA1c and the risk of hypoglycaemia.53, 54. The gene discussed is INS; the disease is type 1 diabetes mellitus.